Cybin Inc (HELP) Stock Forecast & Price Target

Helus Pharma is well-positioned because its lead asset HLP003 has completed enrollment in the Phase 3 APPROACH adjunct MDD study, with topline data due around mid-Nov 2026, sharply improving visibility on a near-term binary catalyst. The company also benefits from de-risking precedent data, including a ~13-point placebo-adjusted MADRS improvement for HLP003 in Phase 2 and external validation from positive pivotal psychedelic trials, while HLP004 adds a second shot on goal in generalized anxiety disorder. Fundamentally, the positive outlook is reinforced by a seasoned neuropsychiatry CEO, supportive regulatory and policy tailwinds, and modeled peak U.S. sales of $1.3B for HLP003 and ~$1.5B for HLP004.

Helus Pharma is a clinical-stage biotechnology company whose valuation hinges on HLP003 and HLP004 advancing through development, yet any clinical failure, stronger competing data, or regulatory setback could severely undermine expected returns. Despite $157.3 million of cash as of March 31 and a $50 million raise on June 25, 2026, the business still faces heavy capital needs in a volatile funding environment, while higher-than-expected R&D and SG&A highlight ongoing burn. The outlook is further pressured by delayed launch assumptions to F2029E and F2030E, and by the inherent uncertainty of turning projected peak revenues of ~$3.9 billion and ~$1.6 billion into realized commercial value.